MX341463B - Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. - Google Patents
Eficacia superior de anticuerpos cd37 en muestras de sangre de cll.Info
- Publication number
- MX341463B MX341463B MX2012013613A MX2012013613A MX341463B MX 341463 B MX341463 B MX 341463B MX 2012013613 A MX2012013613 A MX 2012013613A MX 2012013613 A MX2012013613 A MX 2012013613A MX 341463 B MX341463 B MX 341463B
- Authority
- MX
- Mexico
- Prior art keywords
- patients
- risk
- cll
- treatment
- antibodies
- Prior art date
Links
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 title abstract 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 title abstract 2
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 2
- 206010066901 Treatment failure Diseases 0.000 abstract 1
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 abstract 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 abstract 1
- 229960000548 alemtuzumab Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000000349 chromosome Anatomy 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 229960000390 fludarabine Drugs 0.000 abstract 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 238000010837 poor prognosis Methods 0.000 abstract 1
- 229960004641 rituximab Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10169795 | 2010-07-16 | ||
| EP10175586 | 2010-09-07 | ||
| PCT/EP2011/062133 WO2012007576A1 (en) | 2010-07-16 | 2011-07-15 | Superior efficacy of cd37 antibodies in cll blood samples |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012013613A MX2012013613A (es) | 2012-12-17 |
| MX341463B true MX341463B (es) | 2016-08-22 |
Family
ID=44546328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012013613A MX341463B (es) | 2010-07-16 | 2011-07-15 | Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20120189618A1 (enExample) |
| EP (2) | EP3252077A1 (enExample) |
| JP (2) | JP2013538790A (enExample) |
| KR (1) | KR20130100918A (enExample) |
| CN (2) | CN103003309A (enExample) |
| AU (1) | AU2011278227B2 (enExample) |
| BR (1) | BR112013001012A2 (enExample) |
| CA (1) | CA2799036A1 (enExample) |
| CL (1) | CL2013000101A1 (enExample) |
| EA (1) | EA025365B1 (enExample) |
| IL (1) | IL222775A (enExample) |
| MX (1) | MX341463B (enExample) |
| NZ (2) | NZ703225A (enExample) |
| PH (1) | PH12013500118A1 (enExample) |
| WO (1) | WO2012007576A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| EP2841099A1 (en) * | 2012-04-26 | 2015-03-04 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with bendamustine |
| EP2849784A1 (en) | 2012-05-16 | 2015-03-25 | Boehringer Ingelheim International GmbH | Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide) |
| SG11201707089WA (en) * | 2015-04-13 | 2017-10-30 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
| US11578115B2 (en) | 2017-01-10 | 2023-02-14 | The General Hospital Corporation | Chimeric antigen receptors based on alternative signal 1 domains |
| JP7254710B2 (ja) * | 2017-03-16 | 2023-04-10 | ザ ジェネラル ホスピタル コーポレイション | Ｃｄ３７を標的にするキメラ抗原受容体 |
| WO2018178396A1 (en) | 2017-03-31 | 2018-10-04 | Genmab Holding B.V. | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| JP7513530B2 (ja) | 2018-06-22 | 2024-07-09 | ジェンマブ ホールディング ビー．ブイ． | 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法 |
| WO2020070313A1 (en) | 2018-10-04 | 2020-04-09 | Genmab Holding B.V. | Pharmaceutical compositions comprising bispecific anti-cd37 antibodies |
| WO2023057595A1 (en) | 2021-10-06 | 2023-04-13 | Nordic Nanovector Asa | Humanized hh1 rew |
| US20250333531A1 (en) | 2021-10-06 | 2025-10-30 | Nordic Nanovector Asa | Humanized hh1 |
| WO2025083205A1 (en) | 2023-10-18 | 2025-04-24 | Debiopharm International S.A. | Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US20080279850A1 (en) * | 2005-07-25 | 2008-11-13 | Trubion Pharmaceuticals, Inc. | B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules |
| DK2298815T3 (en) * | 2005-07-25 | 2015-06-15 | Emergent Product Dev Seattle | B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES |
| CN101990439A (zh) * | 2007-07-06 | 2011-03-23 | 特鲁比昂药品公司 | 具有置于c末端的特异性结合结构域的结合肽 |
| PE20120259A1 (es) * | 2007-08-09 | 2012-04-04 | Boehringer Ingelheim Int | Anticuerpos anti-cd37 |
| RS51975B (sr) * | 2008-04-11 | 2012-02-29 | Emergent Product Development Seattle Llc. | Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom |
| AU2009313877A1 (en) * | 2008-11-13 | 2011-06-30 | Emergent Product Development Seattle, Llc | CD37 immunotherapeutic combination therapies and uses thereof |
-
2011
- 2011-07-14 US US13/182,471 patent/US20120189618A1/en not_active Abandoned
- 2011-07-15 MX MX2012013613A patent/MX341463B/es active IP Right Grant
- 2011-07-15 JP JP2013519111A patent/JP2013538790A/ja active Pending
- 2011-07-15 EP EP17174088.9A patent/EP3252077A1/en not_active Withdrawn
- 2011-07-15 AU AU2011278227A patent/AU2011278227B2/en not_active Ceased
- 2011-07-15 EP EP11732464.0A patent/EP2593479A1/en not_active Withdrawn
- 2011-07-15 BR BR112013001012A patent/BR112013001012A2/pt not_active IP Right Cessation
- 2011-07-15 NZ NZ703225A patent/NZ703225A/en not_active IP Right Cessation
- 2011-07-15 CN CN2011800349727A patent/CN103003309A/zh active Pending
- 2011-07-15 CN CN201610095143.4A patent/CN105749276A/zh active Pending
- 2011-07-15 EA EA201201660A patent/EA025365B1/ru not_active IP Right Cessation
- 2011-07-15 CA CA2799036A patent/CA2799036A1/en not_active Abandoned
- 2011-07-15 KR KR1020127032811A patent/KR20130100918A/ko not_active Ceased
- 2011-07-15 WO PCT/EP2011/062133 patent/WO2012007576A1/en not_active Ceased
- 2011-07-15 PH PH1/2013/500118A patent/PH12013500118A1/en unknown
- 2011-07-15 NZ NZ603161A patent/NZ603161A/en not_active IP Right Cessation
-
2012
- 2012-10-31 IL IL222775A patent/IL222775A/en active IP Right Grant
-
2013
- 2013-01-10 CL CL2013000101A patent/CL2013000101A1/es unknown
- 2013-04-26 US US13/871,345 patent/US20130236454A1/en not_active Abandoned
-
2015
- 2015-04-13 US US14/684,928 patent/US20150266967A1/en not_active Abandoned
-
2016
- 2016-07-28 JP JP2016148217A patent/JP2017019800A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011278227A1 (en) | 2012-11-15 |
| EP3252077A1 (en) | 2017-12-06 |
| NZ703225A (en) | 2016-11-25 |
| EP2593479A1 (en) | 2013-05-22 |
| JP2013538790A (ja) | 2013-10-17 |
| CN103003309A (zh) | 2013-03-27 |
| CN105749276A (zh) | 2016-07-13 |
| BR112013001012A2 (pt) | 2016-05-24 |
| US20120189618A1 (en) | 2012-07-26 |
| CL2013000101A1 (es) | 2013-12-27 |
| PH12013500118A1 (en) | 2013-03-11 |
| US20150266967A1 (en) | 2015-09-24 |
| KR20130100918A (ko) | 2013-09-12 |
| EA201201660A1 (ru) | 2013-07-30 |
| US20130236454A1 (en) | 2013-09-12 |
| MX2012013613A (es) | 2012-12-17 |
| CA2799036A1 (en) | 2012-01-19 |
| IL222775A0 (en) | 2012-12-31 |
| WO2012007576A1 (en) | 2012-01-19 |
| NZ603161A (en) | 2015-02-27 |
| JP2017019800A (ja) | 2017-01-26 |
| EA025365B1 (ru) | 2016-12-30 |
| AU2011278227B2 (en) | 2017-03-02 |
| IL222775A (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX341463B (es) | Eficacia superior de anticuerpos cd37 en muestras de sangre de cll. | |
| Li et al. | Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1 | |
| Ye et al. | Anisomycin inhibits angiogenesis in ovarian cancer by attenuating the molecular sponge effect of the lncRNA‑Meg3/miR‑421/PDGFRA axis | |
| Qu et al. | MicroRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene | |
| Li et al. | MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9 | |
| Liang et al. | BMP-7 attenuated silica-induced pulmonary fibrosis through modulation of the balance between TGF-β/Smad and BMP-7/Smad signaling pathway | |
| Han et al. | ROBO3 promotes growth and metastasis of pancreatic carcinoma | |
| Kipper et al. | Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas | |
| Guo et al. | miR-656 inhibits glioma tumorigenesis through repression of BMPR1A | |
| Kang et al. | Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1 | |
| BR112016029713A2 (pt) | métodos para o tratamento de sobrepeso ou obesidade | |
| Sun et al. | MiR-532 downregulation of the Wnt/β-catenin signaling via targeting Bcl-9 and induced human intervertebral disc nucleus pulposus cells apoptosis | |
| WO2017007941A2 (en) | Compositions and methods for identification, assessment prevention, and treatment of cancer using slncr isoforms | |
| Liu et al. | MiR‐96 regulates bone metabolism by targeting osterix | |
| WO2019083971A1 (en) | METHODS OF TREATING CANCER USING LSD1 INHIBITORS IN COMBINATION WITH IMMUNOTHERAPY | |
| Wu et al. | Zinc finger protein 191 inhibits hepatocellular carcinoma metastasis through discs large 1‐mediated yes‐associated protein inactivation | |
| Wang et al. | LINC00511 promotes gastric cancer progression by regulating SOX4 and epigenetically repressing PTEN to activate PI3K/AKT pathway | |
| Zuo et al. | Inhibition of HHIP promoter methylation suppresses human gastric cancer cell proliferation and migration | |
| Song et al. | LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p | |
| Yi et al. | Epigenetically altered miR-1247 functions as a tumor suppressor in pancreatic cancer | |
| Kang et al. | Genetic and non-genetic factors affecting the visual outcome of ocular Behcet’s disease | |
| MX2010010799A (es) | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. | |
| Huang et al. | Long noncoding RNA SNHG1 promotes human prostate cancer progression by sponging miR-383-5p | |
| Liu et al. | MicroRNA-873 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/β-catenin pathway | |
| Xie et al. | CDH4 suppresses the progression of salivary adenoid cystic carcinoma via E-cadherin co-expression |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |